XML 203 R130.htm IDEA: XBRL DOCUMENT
v3.22.4

Provisions and other non-current liabilities (Details 3) $ in Millions | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($)
--- | --- | --- | ---
Disclosure of other provisions [line items] |  |  |
Product liability, government investigations, other legal matters provisions | $ 154.0 | $ 341.0 | $ 181.0
Italy | Lucentis [member] |  |  |
Disclosure of other provisions [line items] |  |  |
Estimated financial effect of contingent liabilities, maximum fine | 1,300.0 |  |
Estimated financial effect of contingent liabilities, damages claimed | 330.0 |  |
Italy | NAG and Novartis Pharma SpA [member] | Lucentis [member] |  |  |
Disclosure of other provisions [line items] |  |  |
Estimated financial effect of contingent liabilities | 125.0 |  |
US | Exforge Group [member] |  |  |
Disclosure of other provisions [line items] |  |  |
Amount of settlement in principle | $ 245.0 |  |
US | Sandoz [member] |  |  |
Disclosure of other provisions [line items] |  |  |
Description of nature of obligation contingent liabilities, number of states with alleged violations | 50 |  |
Amount of settlement in principle |  | 185.0 | 195.0
US | Sandoz [member] | Taxotere [member] |  |  |
Disclosure of other provisions [line items] |  |  |
Product liability contingency, loss exposure not accrued, number of cases | 3,100 |  |
US | Sandoz [member] | Amiodarone [member] |  |  |
Disclosure of other provisions [line items] |  |  |
Product liability contingency, loss exposure not accrued, number of cases | 2 |  |
US | NPC and others [member] | Reclast/Aclasta [member] |  |  |
Disclosure of other provisions [line items] |  |  |
Product liability contingency, loss exposure not accrued, number of cases | 20 |  |
US | NPC and others [member] | Tasigna [member] |  |  |
Disclosure of other provisions [line items] |  |  |
Product liability contingency, loss exposure not accrued, number of cases | 400 |  |
France | F Hoffman La Roche AG and Roche SpA [member] |  |  |
Disclosure of other provisions [line items] |  |  |
Estimated financial effect of contingent liabilities, maximum fine |  |  | $ 452.0
Greece | Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member] |  |  |
Disclosure of other provisions [line items] |  |  |
Estimated financial effect of contingent liabilities, maximum fine |  | $ 1.2 |
Estimated financial effect of contingent liabilities, compensation for moral damages | $ 225.0 |  |

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOtherProvisionsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 37 -IssueDate 2022-03-24 -Paragraph 86 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86_a&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_EstimatedFinancialEffectOfContingentLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_AmountOfSettlementInPrinciple
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations
Namespace Prefix: | nvs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This expresses a maximal amount. + References No definition available. + Details
Name: | nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases
Namespace Prefix: | nvs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_IT
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NAGAndNovartisPharmaSpAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TaxotereMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AmiodaroneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NPCAndOthersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ReclastAclastaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_FR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_FHoffmanLaRocheAGAndRocheSpAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_GR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |